

# Fei Yang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1802932/publications.pdf>

Version: 2024-02-01

16  
papers

611  
citations

840776

11  
h-index

940533

16  
g-index

16  
all docs

16  
docs citations

16  
times ranked

1219  
citing authors

#	ARTICLE	IF	CITATIONS
1	TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer. <i>Modern Pathology</i> , 2021, 34, 710-719.	5.5	90
2	Interobserver Agreement Between Pathologists Assessing Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer Using Methodology Proposed by the International TILs Working Group. <i>Annals of Surgical Oncology</i> , 2016, 23, 2242-2248.	1.5	85
3	Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy. <i>Cancers</i> , 2019, 11, 714.	3.7	79
4	The Immune Microenvironment in Hormone Receptor-Positive Breast Cancer Before and After Preoperative Chemotherapy. <i>Clinical Cancer Research</i> , 2019, 25, 4644-4655.	7.0	76
5	Increased VEGFR-2 Gene Copy Is Associated with Chemoresistance and Shorter Survival in Patients with Non-Small-Cell Lung Carcinoma Who Receive Adjuvant Chemotherapy. <i>Cancer Research</i> , 2011, 71, 5512-5521.	0.9	55
6	Sphingosine Kinase 1 Signaling Promotes Metastasis of Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2019, 79, 4211-4226.	0.9	48
7	Atypical plant homeodomain of UBR7 functions as an H2BK120Ub ligase and breast tumor suppressor. <i>Nature Communications</i> , 2019, 10, 1398.	12.8	35
8	A functional genomic screen in vivo identifies CEACAM5 as a clinically relevant driver of breast cancer metastasis. <i>Npj Breast Cancer</i> , 2018, 4, 9.	5.2	32
9	First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models. <i>Breast Cancer Research</i> , 2021, 23, 29.	5.0	31
10	Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5365-5375.	7.0	29
11	CD8+ T cells inhibit metastasis and CXCL4 regulates its function. <i>British Journal of Cancer</i> , 2021, 125, 176-189.	6.4	21
12	Effector memory cytotoxic CD3+/CD8+/CD45RO+ T cells are predictive of good survival and a lower risk of recurrence in triple-negative breast cancer. <i>Modern Pathology</i> , 2022, 35, 601-608.	5.5	10
13	The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial. <i>Investigational New Drugs</i> , 2021, 39, 829-835.	2.6	8
14	A 95-gene signature stratifies recurrence risk of invasive disease in ER-positive, HER2-negative, node-negative breast cancer with intermediate 21-gene signature recurrence scores. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 455-461.	2.5	6
15	Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancers. <i>Npj Breast Cancer</i> , 2022, 8, 64.	5.2	3
16	Tumor Immune Microenvironment Changes by Multiplex Immunofluorescence Staining in a Pilot Study of Neoadjuvant Talazoparib for Early-Stage Breast Cancer Patients with a Hereditary BRCA Mutation. <i>Clinical Cancer Research</i> , 2022, 28, 3669-3676.	7.0	3